This edition of the epistles of Doc Gumshoe won’t be entirely about Alzheimer’s, but there are Alzheimer’s-related news items that jump to the top, based on timeliness, if nothing more. When Doc Gumshoe last wrote about what was happening on the Alzheimer’s front, a big chunk of the piece was the FDA’s surprising – and […]
Articles
Ed. Note: This article was originally posted on June 15, 2021. It is being re-run here because we’re getting questions as this is touted as a “brand new buy alert” in recent ads, the ads themselves have not changed and this particular article has not been updated since publication. FYI: The stock teased, DNLI, is […]
Which means, the more things change, the more they stay the same. The big change in the Alzheimer’s disease world – which you’ve all heard about, no doubt – is that the FDA granted emergency use authorization to aducanumab, now to be named Aduhelm. That happened on the 6th of June. The FDA’s decision elicited […]
Everyone loves a good “this’ll cure Alzheimer’s!” story… both because we all know someone who has been touched by this awful disease, and because we know that a cure for Alzheimer’s would likely be a multi-billion-dollar drug. So the pundits tease early-stage hopefuls quite often, they fail almost all the time, and we keep hoping […]
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
The many welcome comments to the Alzheimer’s piece that posted a couple of weeks ago prompt me to supply answers (if I am able to do that), but also set my mind to wandering on the fringes of a number of issues that may be of interest to the Gumshoe constituency. Anavex 2-73 At the […]
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and small revealing the unfortunate news that yet another promising agent for the treatment of AD has failed to meet its objectives in a […]
I have no idea what’s going to happen in the market today, but perhaps if I spend my time looking into a teaser pitch from a new newsletter I’ll be too busy to obsess over my portfolio and do something dumb during the trade war panic gyrations. Sound good? Want to join me? Great! The […]
Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]
Is this going to be good news, or bad news, or somewhere in between? On balance, I would say good news, simply because the research and investigation is going on at an intense pace. Currently there are 1,903 clinical trials underway at some stage, in the US and all over the world. When I first […]
Alzheimer’s Disease always gets a lot of attention from newsletter publishers, readers and investors — not only because we all know someone who suffers from this terrible malady, but because we know that the current treatments are ineffective and the market is huge… which means that any real solutions or more effective treatments could create […]
Dave Lashmet has teased a handful of biotech stocks since starting the Stansberry Venture service a couple years ago, and they usually get a lot of attention from our readers — so the new ad from Lashmet today has been forwarded to me dozens of times already. And while I’m not sure we’ll be able […]
Alzheimer’s Wrap-Up[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes about health and medicine for us from time to time. His columns are not generally focused on investments, though this one does include some commentary about a number of specific companies (most are not publicly traded). His words and opinions are his own, […]
[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the […]
[Ed Note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he sometimes mentions a couple publicly traded companies). His words and opinions are his own. […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Michael Jorrin, who we like to call “Doc Gumshoe”, is a medical writer who shares his thoughts with us once or twice a month. He does not usually recommend or discuss investments, and, as with all of our contributors, his words are his own and he chooses his own topics.] To start us off, three […]
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way that makes sense. The words and opinions shared below are his alone. If you’re curious about whether rheumatoid arthritis matters to […]
[ed note: This is another installment from our favorite medical writer, Doc Gumshoe (no, he’s not a doctor, but we like the way he analyzes and explains medical issues for our readers). Since he’s talking about specific companies this time, we’ve restricted the piece to the Irregulars and have inserted some comments about the stocks […]
I thought we might be done for the year … but before we turn out the lights here at Gumshoe HQ for our Christmas week vacation, I couldn’t resist sharing one last teaser tidbit for you — after all, if you’re thinking about what to do with your money next year, what could be better […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I subscribed to Lashmet's letter three years ago. While I did not take all of his suggestions, I did invest in BIIB, IN...
In both SAVA and AVXL. Personal and financial reasons. Getting a lot of added interest today with BIIB approval....
Eisai is a partner with Biogen on aducanumab. ESALY is < $90 per share as opposed to BIIB at $285. ....
I'm afraid Deb109 could be correct in his statement, and you should look in one of these tickers; VIR OSUR TSE: 4528 ...
FYI, some more cautious perspectives On “repurposing” analysis to rescue the drug trial last year: https://www.s...
I think this maybe BIIB. Biogen. ?...
Check the timing of BIIB Mgt's bonus, stock options The cynic in me says they needed to hit a target level to cash in th...
Another failure in Alzheimer's Disease trials... BIIB and Eisai discontinued their late Phase 3 trials because they were...